We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 12, 2021

Glucose-Lowering Therapies Prescription and COVID-19 Mortality in People With T2D

The Lancet Diabetes & Endocrinology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Prescription of Glucose-Lowering Therapies and Risk of COVID-19 Mortality in People With Type 2 Diabetes: A Nationwide Observational Study in England
Lancet Diabetes Endocrinol 2021 Mar 30;[EPub Ahead of Print], K Khunti, P Knighton, F Zaccardi, C Bakhai, E Barron, N Holman, P Kar, C Meace, N Sattar, S Sharp, NJ Wareham, A Weaver, E Woch, B Young, J Valabhji

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading